Benzinga | Jan 4, 2021 05:52AM EST

Genetic Technologies Named Simon Morriss as CEO

Genetic Technologies Limited (NASDAQ:GENE), announces the appointment of Simon Morriss to the role of Chief Executive Officer, commencing on 1 February 2021. Simon brings over 20 years' experience within the Pharmaceutical, Healthcare and FMCG industries having held senior executive positions at Sanofi and Blackmores. He brings a wealth of experience in managing teams and successfully executing across sales, marketing and brand building. Additionally, he has been critical in leading commercialisation across these industries and understands the unique pressures and opportunities. Simon has led companies through strategic adaptation to execution and will be driving Genetic Technologies commercialisation strategy and continue to drive innovation across the business.

Additionally, the Board is pleased to announce that George Muchnicki, who has been Acting CEO since September 2019, will be stepping into the role of Chief Medical Officer and Executive Director. George was critical in advancing both the direction of the Company and the scope of the products in development. In his role as Chief Medical Officer, George will continue to leverage his exceptional background and experience to continue to advance the product development and establish the medical framework for GTGs platform offering.